ProSolus, Inc. Chief Operating Officer Named to PharmaVOICE 100 Most Inspiring People
Juan Mantelle honored for his innovation in transdermal drug development.
SAN ANTONIO (August 8, 2016) – Mission Pharmacal Company today announced that Juan Mantelle, Chief Operating Officer of its wholly-owned subsidiary ProSolus®, Inc., has been named to PharmaVOICE magazine’s prestigious annual list of the 100 most inspiring people in the life sciences. These elite recipients are moving the industry forward and improving all aspects of healthcare by imagining, creating, and executing new possibilities.
Mantelle was recognized for his innovative and unique approach of using patch technology for transdermal drug delivery. Patches need to adhere to the skin without irritation, wear well for the duration of treatment, and not lose skin contact. To many, discovering how to deliver the precise amount of drug through the skin to treat the patient is an art form, and Mantelle has used creative ways to improve transdermal products and employ his scientific and manufacturing skills to turn ideas into reality. Mantelle produces patches that meet stringent regulatory requirements. He has also improved wearability of patches by creating smaller, more desirable products that stay in place while exercising, bathing or swimming. His work inspires others to continue to develop further therapies using this unique delivery system.
Mantelle has devoted more than 30 years to continually creating new applications with novelty, effectiveness, and ingenuity. He is considered a guru in the drug delivery arena, at times referred to as the “Picasso” of his field.
Mission Pharmacal acquired ProSolus in 2015. This allowed Mantelle to focus on his passion of developing products with unique market potential and great therapeutic value. He currently holds 23 patents, is in demand to speak at symposia and conferences worldwide, and simultaneously leads his research and development team to produce generic and over-the-counter transdermal products.
“Juan is well-deserving of this recognition by PharmaVOICE,” notes Mission Pharmacal President and 2015 PharmaVOICE 100 honoree, Neill “Gobie” Walsdorf, Jr. “Prior to our acquisition of ProSolus, we were admirers of his work. Becoming business partners and having Juan and his team as part of the Mission family strengthens and broadens our overall product portfolio and manufacturing capabilities. We’re excited that we can now offer the convenience of cutting-edge transdermal technology to healthcare providers and patients across the country and have noted PharmaVOICE leadership imbedded in our Mission Pharmacal culture.”
Established more than 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life science industry. Selected from thousands of nominations, honorees are selected based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and competitors; have affected positive changes in their own organizations; and continually give back to their communities and other philanthropic causes. To view Mantelle’s complete PharmaVOICE 100 profile, please visit the July/August 2016 online digital edition at pharmavoice.com.About ProSolus, Inc.
ProSolus®, Inc. is a wholly-owned subsidiary of Mission Pharmacal Company. The company offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal and trans-mucosal drug delivery products to treat a variety of health conditions. For more information, please visit prosoluspharma.com.
ProSolus, Inc. is part of the Mission family of companies that also includes BioComp Pharma, Inc., a generic drug distributor; Alamo Pharma Services, Inc., a specialized contract sales organization; Espada Dermatology, Inc., an esthetic dermatology company; and BexR Logistix, LLC, a logistics and fulfillment company. To learn more, please visit missionpharmacal.com.
Integrated Marketing and Communications